In recent years, targeted drugs against BRAF have shown remarkable therapeutic success for a subset of patients with advanced malignancies including melanoma, non-small cell lung cancer (NSCLC) and other malignancies, leading to their FDA approval. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.